Xolair (omalizumab) - Roche, Novartis
Study on the Immune Characteristics and Predictive Biomarkers of Omalizumab Response in Chronic Spontaneous Urticaria (ChiCTR) - Oct 16, 2026 - P=N/A | N=508 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University 
New trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
https://www.chictr.org.cn/showproj.html?proj=320514
 
Oct 16, 2026
 
Prev Next